Research demonstrating the remarkable cancer-killing power of genetically rewired white blood cells — known as CAR-T therapy — has long grabbed the spotlight at the annual meeting of the American Society of Hematology.
This year, though, the debate is no longer about whether or not CAR-T kills cancer. New research to be presented at the conference, kicking off Saturday in Atlanta, will focus instead on the long-term durability of CAR-T, the potential to target different types of blood cancers, and the feasibility of treating large numbers of patients scattered across the globe.
About the Author Reprints
Keep proprietary products off twitter please- keep it free